High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis
Authors:
- 1 September 2021
- journal article
- research article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 358, 577634
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Health, Labour and Welfare (20FC1030)
This publication has 19 references indexed in Scilit:
- Serum cytokine and chemokine profiles in patients with myasthenia gravisClinical and Experimental Immunology, 2014
- T Helper Type 17 Cells Expand in Patients with Myasthenia‐Associated ThymomaScandinavian Journal of Immunology, 2012
- Blocking of IL-6 suppresses experimental autoimmune myasthenia gravisJournal of Autoimmunity, 2011
- Increased serum interleukin‐17 levels in patients with myasthenia gravisMuscle & Nerve, 2011
- Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis opticaProceedings of the National Academy of Sciences, 2011
- Autoimmune myasthenia gravis: emerging clinical and biological heterogeneityThe Lancet Neurology, 2009
- Myasthenia gravis: past, present, and futureJournal of Clinical Investigation, 2006
- Altered expression of chemokine receptor CXCR5 on T cells of myasthenia gravis patientsJournal of Neuroimmunology, 2005
- Selective loss of regulatory T cells in thymomasAnnals of Neurology, 2004
- Myasthenia gravisNeurology, 2000